Approach to “Aspirin Allergy” in Cardiovascular Patients
2004; Lippincott Williams & Wilkins; Volume: 110; Issue: 1 Linguagem: Inglês
10.1161/01.cir.0000134306.28561.2a
ISSN1524-4539
AutoresSrinivasan Ramanuja, Jeffrey A. Breall, Vijay G. Kalaria,
Tópico(s)Acute Myocardial Infarction Research
ResumoHomeCirculationVol. 110, No. 1Approach to "Aspirin Allergy" in Cardiovascular Patients Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBApproach to "Aspirin Allergy" in Cardiovascular Patients Srinivasan Ramanuja, Jeffrey A. Breall and Vijay G. Kalaria Srinivasan RamanujaSrinivasan Ramanuja From the Krannert Institute of Cardiology, Clarian Cardiovascular Center, Department of Medicine, Indiana University School of Medicine, Indianapolis, Ind. , Jeffrey A. BreallJeffrey A. Breall From the Krannert Institute of Cardiology, Clarian Cardiovascular Center, Department of Medicine, Indiana University School of Medicine, Indianapolis, Ind. and Vijay G. KalariaVijay G. Kalaria From the Krannert Institute of Cardiology, Clarian Cardiovascular Center, Department of Medicine, Indiana University School of Medicine, Indianapolis, Ind. Originally published6 Jul 2004https://doi.org/10.1161/01.CIR.0000134306.28561.2ACirculation. 2004;110:e1–e4Aspirin (ASA), by irreversibly inhibiting platelet cyclooxygenase-1 enzyme (COX-1), prevents platelet aggregation and is the mainstay of pharmacotherapy of patients with coronary artery disease (CAD). Long-term ASA therapy reduces mortality in CAD patients after an initial coronary event. Periprocedural ASA therapy significantly reduces major adverse cardiovascular events (MACE) after percutaneous coronary interventions.1,2 Despite a plethora of clinical data showing marked efficacy of ASA therapy in cardiovascular patients, ASA use continues to be less than optimal in real-world registries.3,4 A history of adverse reactions to ASA may prevent long-term use in a cardiovascular patient, thereby reducing optimal event protection. Most adverse reactions to ASA, such as gastrointestinal intolerance, are predictable and are dose and host related.5 However, ASA can also cause a hypersensitivity reaction, of which there are 3 types: respiratory sensitivity (asthma and/or rhinitis), cutaneous sensitivity (urticaria and/or angioedema), and systemic sensitivity (anaphylactoid reaction).6 Various terms have been used to describe the hypersensitivity reactions to ASA, including ASA intolerance, ASA idiosyncrasy, pseudoallergic reactions, and ASA sensitivity.7 The prevalence of ASA sensitivity in cardiovascular patients is not well known. Besides substitution with an alternative class of antiplatelet agents such as thienopyridines, ASA desensitization is an option for ASA-allergic patients who require long-term therapy for cardiovascular diseases.7In this article, we review various hypersensitivity reactions to ASA and discuss desensitization protocols to allow ASA therapy in ASA-sensitive cardiovascular patients.Adverse Reactions to ASAASA-Exacerbated Respiratory DiseaseASA-exacerbated respiratory disease (AERD) is a triad of asthma, ASA sensitivity, and rhinitis/nasal polyps. Patients with AERD have aggressive mucosal inflammation and suffer from precipitation of asthma and rhinitis after ingestion of ASA and nonsteroidal antiinflammatory drugs (NSAIDs).8 AERD is also commonly referred to as ASA-sensitive, ASA-induced, or ASA-intolerant asthma. AERD is the cause of 10% to 15% of all cases of asthma,8 is usually seen in adulthood, and has a higher prevalence in females. Determination of patients who are at the highest risk for AERD presents a clinical challenge. Most patients with AERD have moderate or severe persistent asthma and suffer from nasal polyposis and recurrent sinus infections.9 Thus, the presence of underlying moderate or severe persistent asthma can be considered a significant risk factor for AERD. There has been a case report of AERD in multiple members of one family10; however, familial occurrence is rare, and thus a family history is not necessarily a risk factor for AERD.Inhibition of the COX-1 enzyme by ASA and NSAIDs decreases the production of prostaglandins (PGs), most importantly PGE2. PGE2, an inhibitor of 5-lipoxygenase enzyme, has a modulating effect on mast cells. Decreased availability of PGE2 preferentially stimulates the 5-lipoxygenase pathway, leading to an increase in leukotrienes (LTs).7 Several LTs (especially LTC4, LTD4, and LTE4) mediate eosinophil chemotaxis, increase vascular permeability and mucus gland secretion, and precipitate bronchoconstriction.7 Those LTs have also been shown to elicit a wheal and flare reaction when administered subcutaneously to patients.11 At this time, it is not completely understood why the interruption of PGE2 by ASA and NSAIDs causes respiratory reactions in some humans but not others. Alternate modulators of the prostaglandins–leukotrienes pathway or differences in structure or susceptibility of COX enzymes may account for varied susceptibility of patients to ASA.8NSAIDs (ASA)-Induced Cutaneous DiseaseCutaneous reactions to NSAIDs consist of urticaria, which can occur separately or simultaneously with angioedema. These reactions also tend to occur more in adulthood and in young females.12 Cutaneous reactions to ASA have been documented to occur more frequently in atopic individuals (persons with a hereditary predisposition toward developing certain hypersensitivity reactions such as hay fever, asthma, or urticaria).13 Additionally, NSAIDs exacerbate urticaria in one third to two thirds of patients with chronic idiopathic urticaria.14The postulated mechanism for cutaneous reactions, just as for the respiratory reactions, is the increased production of leukotrienes resulting from COX-1 inhibition.14 One support of this "cyclooxygenase theory" is the demonstration that pretreatment with leukotriene-receptor antagonists can block NSAID-induced urticaria and angioedema reactions.14In addition to NSAIDs class-related urticaria and angioedema, Stevenson et al15 describe single-drug anaphylaxis and blended reactions. In single-drug anaphylaxis, after the initial drug exposure and sensitization, subsequent drug exposure leads to cutaneous reactions plus respiratory symptoms. Single-drug anaphylactic reactions are presumed to be immunoglobulin E mediated and lack cross-reactivity with other NSAIDs. Blended reactions consist of a mixed clinical picture of urticaria and/or angioedema, cough, dyspnea, hoarseness, wheezing, rhinorrhea, and/or tearing.ASA-Induced Anaphylactoid ReactionsAnaphylactoid reactions occur within minutes of ingesting ASA and are characterized by hypotension, swelling, laryngeal edema, generalized pruritus, tachypnea, and lapses in consciousness.6 Angioedema with hypotension is generally considered an anaphylactoid reaction rather than a cutaneous reaction to ASA. Because specific immunoglobulin E against ASA has not been found, these reactions are called anaphylactoid and are clinically indistinguishable from anaphylactic reactions.7 The treatment for anaphylactoid reactions is the same as that for anaphylactic reactions.ASA Challenge and Desensitization ProtocolsNo in vitro test exists that can identify patients with ASA hypersensitivity; the only way to definitively make the diagnosis is through provocative ASA challenge, namely oral, bronchial or nasal routes (only oral ASA challenges are available in the United States).7 Even cutaneous tests have failed to consistently elicit wheal and flare responses.6Several successful desensitization protocols are available that involve oral challenge and dosing intervals of up to 24 hours. ASA challenge should not be performed purely for diagnostic purpose, as some of the reactions can be quite severe. In unstable patients with CAD and recent stent placement, it becomes necessary to devise protocols that would allow ASA therapy to be administered safely within a few hours.16Desensitization Protocols for Patients With AERDSzcezeklik and Stevenson8 described a strategy for desensitizing patients with AERD. This protocol, also referred to as "Scripps Clinic Protocol," involves small incremental oral doses of ASA administered over the course of 2 to 3 days, until 400 to 650 mg of ASA is tolerated (Table 1). They recommend that ASA desensitization, followed by daily ASA treatment, be considered a therapeutic option for the following groups of patients with AERD: those whose disease can be controlled only with unacceptably high doses of systemic corticosteroids; those who require repeated nasal polypectomies and/or sinus surgery, even if they are not taking systemic corticosteroids; and those who need ASA/NSAIDs for the treatment of other diseases, such as CAD, arthritis, or thromboembolism. TABLE 1. ASA Challenge/Desensitization Protocol8for Patients With AERDTime 0Time 3 hoursTime 6 hoursDay 1PlaceboPlaceboPlaceboDay 2ASA 30 mgASA 60 mgASA 120 mgDay 3ASA 150 mgASA 325 mgASA 650 mgSchaefer and Gore5 reported a 45-year-old female patient with a history of mild asthma and allergic rhinitis and ASA sensitivity. She was hospitalized for a myocardial infarction, treated with coronary stenting, and discharged with ticlodipine 250 mg twice-daily therapy. She underwent the oral ASA challenge test and desensitization in an outpatient setting using a protocol similar to the Scripps Clinic protocol by Szcezeklik and Stevenson,8 described in Table 1. The first day of placebo challenges is done to ensure airway stability with vital signs and pulmonary function measured hourly.1Desensitization Protocols for Patients With ASA/NSAID-Induced Cutaneous ReactionsWong et al16 performed challenge-desensitization studies on 11 patients with history of ASA- or NSAID-induced urticaria or angioedema, 9 of whom had CAD. Ten patients were pretreated with an antihistamine agent and 1 patient received prednisone (60 mg) the night before and the morning of the study. Nine out of 11 patients tolerated the procedure without adverse effects and continued ASA therapy from 1 to 24 months without developing urticaria or angioedema. This protocol (Table 2) is particularly useful in patients with unstable CAD, as it can be completed within a few hours, thus allowing for rapid desensitization. TABLE 2. ASA Challenge/Desensitization Protocols for Patients With ASA-Induced Cutaneous Disease: Wong et al16ProtocolTime, minASA Dose, mg00.1150.33010453060408581110162135325Another protocol described by Schaefer and Gore5 was used on a 40-year-old woman with an anterior myocardial infarction treated with 2-vessel coronary artery bypass surgery. Five years before her infarction she had urticarial facial rash attributed to ASA. A 1-day protocol for the evaluation of ASA-sensitive urticaria was performed (Table 3). She tolerated the challenge well without any dermatologic, respiratory, or systemic reaction and was maintained on ASA 81 mg daily. This protocol is to be used only if there is zero-to-minimum risk of a respiratory/anaphylactoid reaction.1TABLE 3. ASA Challenge/ Desensitization Protocols for Patients With ASA-Induced Cutaneous Disease: Schaefer-Gore5ProtocolTime, h0Placebo/placebo1Placebo/ASA 150 mg2Placebo/ASA 325 mg3Placebo/placebo4ASA 325 mg/ASA 325 mg5Placebo/placebo6EndAt present, ASA desensitization protocols are highly variable without a universally accepted methodology. Any of the aforementioned published ASA challenge/densensitization protocols may be performed based on the preference of the consulting allergist. It is important to optimize overall clinical status of the patient with oral and inhaled corticosteroids, intra-nasal corticosteroids, theophylline, and long-acting bronchodilators before oral ASA challenges, if time permits.7 Antileukotriene modifiers such as zileuton and montelukast can block bronchospastic responses during oral ASA challenges, but often do not inhibit AERD reactions. However, anticholinergics, antihistamines, cromolyn, and short-acting inhaled β-agonists should be discontinued 24 hours before challenge. In patients with chronic idiopathic urticaria, discontinuing antihistamine a day or two before the oral challenge often results in a flare of urticaria, which may coincide with but be unrelated to the drug challenge. As those with active urticaria (at the time of challenge) have a much higher prevalence of ASA sensitivity, antihistamines should be tapered to the lowest effective dose.7 Thus, we recommend discontinuing antihistamines before ASA challenge in a patient with AERD, but continuing antihistamines when doing a challenge in a patient with urticaria. ASA challenge should be attempted when the patient's baseline forced expiratory volume in first minute (FEV1) value is equal to or greater than 70% of best predicted FEV1 value and above an absolute value of 1.5 L.17A classic positive ASA challenge reaction is described as a 20% or greater decrease in FEV1 combined with naso-ocular symptoms (chemosis, tearing, periorbital swelling, nasal congestion, rhinorrhea). Isolated asthmatic (FEV1 decline) or naso-ocular symptoms can also occur.5,7,17 If positive reactions occur during the ASA challenge/desensitization protocol, vigorous symptomatic treatment should be promptly started. After a positive reaction during the desensitization process, subsequent ASA doses will be dependent on the desensitization protocol used.5,8,16,17 Once desensitized, it is prudent to maintain regular ASA therapy to prevent breakthrough ASA allergic reactions.There are no published protocols involving ASA desensitization in individuals known to have an anaphylactoid response to ASA; rather, it seems more practical to use an alternative agent such as thienopyridines.7 Selective COX-2 inhibitors and low-dose acetaminophen are generally safe in patients with ASA sensitivity. The current recommendations from the American College of Cardiology and the American Heart Association regarding ASA desensitization in cardiovascular patients is that if true ASA allergy is present, other antiplatelet agents such as dipyridamole, ticlopidine, or clopidogrel may be substituted. The diagnostic and management approach to cardiovascular patients with a reported history of "ASA allergy" is outlined in the Figure. Download figureDownload PowerPointThe management approach to cardiovascular patients with possible "ASA allergy." ICU indicates intensive care unit; FEV1, forced expiratory volume in first minute.ConclusionASA therapy has been shown to be of extreme benefit for cardiovascular patients, both in primary and secondary prevention of CAD. As described above, allergic reactions to ASA form a clinical spectrum, and not all patients with a reported ASA allergy have ASA-induced anaphylactoid reaction. Avoiding ASA in the patient subsets with AERD and ASA-induced cutaneous reactions would be a significant disadvantage from a long-term pharmacotherapy standpoint for the majority of these patients. Proper classification of "ASA-allergic" patients and early referral to allergy services for potential ASA desensitization will allow use of this highly cost-effective therapy in cardiovascular patients. Population-based studies are needed to better document prevalence of ASA allergy and clinical subtypes in cardiovascular patients. Standardization of an ASA challenge/desensitization protocol will also facilitate optimal management of the cardiovascular patient with ASA allergy.FootnotesCorrespondence to Vijay G. Kalaria, MD, FACC, FSCAI, Associate Director, Catheterization Laboratories and Interventional Cardiology, Krannert Institute of Cardiology, Indiana University School of Medicine, Clarian Cardiovascular Center, E404, 1800 North Capitol Ave, Indianapolis, IN 46202. E-mail [email protected] References 1 Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998; 339: 1665–1671.CrossrefMedlineGoogle Scholar2 Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 1988; 318: 1714–1719.CrossrefMedlineGoogle Scholar3 Hoekstra JW, Pollack CV Jr, Roe MT, et al. Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. Acad Emerg Med. 2002; 9: 1146–1155.CrossrefMedlineGoogle Scholar4 Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 15 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol. 2000; 36: 2056–2063.CrossrefMedlineGoogle Scholar5 Schaefer OP, Gore JM. Aspirin sensitivity: the role for aspirin challenge and desensitization in postmyocardial infarction patients. Cardiology. 1999; 91: 8–13.Google Scholar6 Manning ME, Stevenson DD, Mathison DA. Reactions to aspirin and other nonsteroidal anti-inflammatory drugs. Immunol Allergy Clin North Am. 1992; 12: 611–631.CrossrefGoogle Scholar7 Namazy JA, Simon RA. Sensitivity to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol. 2002; 89: 542–550.CrossrefMedlineGoogle Scholar8 Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol. 1999; 104: 5–13.CrossrefMedlineGoogle Scholar9 Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003; 111: 180–186.CrossrefMedlineGoogle Scholar10 Miller FF. Aspirin-induced bronchial asthma in sisters. Ann Allergy. 1971; 29: 263–265.MedlineGoogle Scholar11 Settipane GA. Aspirin sensitivity and allergy. Biomed Pharmacother. 1988; 42: 493–498.MedlineGoogle Scholar12 Strom BL, Carson JL, Lee Morse M, et al. The effect of indication on hypersensitivity reactions associated with Zomepirac sodium and other nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 1987; 30: 1142–1148.CrossrefMedlineGoogle Scholar13 Sanchez-Borges M, Capriles-Hulett A. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol. 2000; 84: 101–106.CrossrefMedlineGoogle Scholar14 Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Cutaneous reactions to aspirin and nonsteroidal anti-inflammatory drugs. Clin Rev Allergy Immunol. 2003; 24: 125–135.CrossrefMedlineGoogle Scholar15 Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudo-allergic reactions to drugs that inhibit cyclo-oxygenase enzymes. Ann Allergy Asthma Immunol. 2001; 87: 1–4.Google Scholar16 Wong JT, Nagy CS, Krinzman SJ, et al. Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol. 2000; 105: 997–1001.CrossrefMedlineGoogle Scholar17 Pleskow WW, Stevenson DD, Mathison DA, et al. Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol. 1982; 69 (1 Pt 1): 11–19.MedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Naveed H, Akhtar N, Al-Jerdi S, Uy R, Joseph S, Morgan D, Babu B, Shanthi S and Shuaib A (2023) Appropriate use of antiplatelet medications following transient ischemic attacks and stroke: a 9-year study from the Middle East, Frontiers in Neurology, 10.3389/fneur.2023.1269292, 14 Adame M, Raji M, Shan Y, Zhang Y, Kuo Y and Tripple J (2023) Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data, The Journal of Allergy and Clinical Immunology: In Practice, 10.1016/j.jaip.2023.07.014, 11:11, (3445-3453.e6), Online publication date: 1-Nov-2023. Thakker R, Salazar L, Jazar D, Bhakta P, Baker B, Patel C, Elbadawi A, Agarwal M, Albaeni A, Saleh M, Esclovan J, El Haddad D, Alwash H, Kalra A, Goel S, Widmer R, Chatila K, Khalife W, Motiwala A, McCracken J, Jneid H and Gilani S (2022) Coronary Artery Disease and Aspirin Intolerance: Background and Insights on Current Management, Cardiology and Therapy, 10.1007/s40119-022-00255-9, 11:2, (175-183), Online publication date: 1-Jun-2022. Farsad B and Salehi H (2022) Cardiovascular Drugs and Hemostasis Practical Cardiology, 10.1016/B978-0-323-80915-3.00032-6, (701-729), . Corlateanu A, Stratan I, Covantev S, Botnaru V, Corlateanu O and Siafakas N (2021) Asthma and stroke: a narrative review, Asthma Research and Practice, 10.1186/s40733-021-00069-x, 7:1, Online publication date: 1-Dec-2021. Kassimis G, Raina T and Alexopoulos D Aspirin Hypersensitivity in Patients Undergoing Percutaneous Coronary Intervention. What Should We be Doing?, Current Vascular Pharmacology, 10.2174/1570161116666180604100220, 17:4, (326-331) Bianco M, Gravinese C, Cerrato E, Nuñez-Gil I, Destefanis P, Luciano A, Biscaglia S, Quadri G, Tizzani E, Corleto A, Giolitto S, Lo Savio L, Campo G, Varbella F and Pozzi R Management of aspirin intolerance in patients undergoing percutaneous coronary intervention. The role of mono-antiplatelet therapy: a retrospective, multicenter, study, Minerva Cardioangiologica, 10.23736/S0026-4725.19.04787-X, 67:2 Bach R (2019) Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction Cardiac Intensive Care, 10.1016/B978-0-323-52993-8.00012-6, (117-138.e7), . Jadhav K and Chandrasekharan R (2018) A CASE OF MISTAKEN ASPIRIN ALLERGY, Journal of Evidence Based Medicine and Healthcare, 10.18410/jebmh/2018/483, 5:31, (2344-2345), Online publication date: 30-Jul-2018. Al-Sanouri B, Maslamani Y and Sanouri I (2018) A Practical Approach to Demystifying Drug Allergy in the Intensive Care Unit. A Review Article, Open Journal of Internal Medicine, 10.4236/ojim.2018.81008, 08:01, (64-83), . Cortellini G, Romano A, Santucci A, Barbaud A, Bavbek S, Bignardi D, Blanca M, Bonadonna P, Costantino M, Laguna J, Lombardo C, Losappio L, Makowska J, Nakonechna A, Quercia O, Pastorello E, Patella V, Terreehorst I, Testi S, Cernadas J, Dionicio Elera J, Lippolis D, Voltolini S and Grosseto D (2016) Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti-inflammatory drug hypersensitivity, Allergy, 10.1111/all.13068, 72:3, (498-506), Online publication date: 1-Mar-2017. Córdoba-Soriano J, Corbí-Pascual M, López-Neyra I, Navarro-Cuartero J, Hidalgo-Olivares V, Barrionuevo-Sánchez M, Prieto-Mateos D, Gutiérrez-Díez A, Gallardo-López A, Fuentes-Manso R, Gómez-Pérez A, Lafuente-Gormaz C and Jiménez-Mazuecos J (2016) Early aspirin desensitization in unstable patients with acute coronary syndrome: Short and long-term efficacy and safety, European Heart Journal: Acute Cardiovascular Care, 10.1177/2048872615618509, 5:7, (41-50), Online publication date: 1-Nov-2016. Duarte T, Gonçalves S, Sá C, Marinheiro R, Rodrigues R, Seixo F, Tomas E and Caria R (2016) Hypersensitivity to aspirin and urgent percutaneous coronary intervention: A therapeutic challenge, Revista Portuguesa de Cardiologia (English Edition), 10.1016/j.repce.2016.03.010, 35:11, (619.e1-619.e5), Online publication date: 1-Nov-2016. Duarte T, Gonçalves S, Sá C, Marinheiro R, Rodrigues R, Seixo F, Tomas E and Caria R (2016) Hipersensibilidade à aspirina e coronariografia urgente: desafio terapêutico, Revista Portuguesa de Cardiologia, 10.1016/j.repc.2016.03.008, 35:11, (619.e1-619.e5), Online publication date: 1-Nov-2016. Manzo-Silberman S, Nicaise-Roland P, Neukirch C, Tubach F, Huisse M, Chollet-Martin S, Abergel H, Driss F, Alfaiate T, Ajzenberg N and Steg P (2016) Effect of rapid desensitization on platelet inhibition and basophil activation in patients with aspirin hypersensitivity and coronary disease, European Heart Journal - Cardiovascular Pharmacotherapy, 10.1093/ehjcvp/pvw018, (pvw018) Bianco M, Bernardi A, D'Ascenzo F, Cerrato E, Omedè P, Montefusco A, DiNicolantonio J, Zoccai G, Varbella F, Carini G, Moretti C, Pozzi R and Gaita F (2016) Efficacy and Safety of Available Protocols for Aspirin Hypersensitivity for Patients Undergoing Percutaneous Coronary Intervention, Circulation: Cardiovascular Interventions, 9:1, (e002896), Online publication date: 1-Jan-2016. Heuser R, Buelna T, Gold A, Rao R, Van Alstine W, Cooper R and Desai M (2015) NephroBlate™ Renal Denervation System: Urologic-Nephrologic Based Approach to Resistant Hypertension Renal Denervation, 10.1007/978-1-4471-5223-1_15, (125-134), . Agarwal S (2014) Single antiplatelet therapy after percutaneous coronary intervention in patients allergic to aspirin, Cardiovascular Revascularization Medicine, 10.1016/j.carrev.2014.04.005, 15:5, (308-310), Online publication date: 1-Jul-2014. Zuckerman S, Seder D, Tsujiura C, Cushing D, Gallup H, Mocco J, Hanel R and Ecker R (2014) Aspirin Allergy Desensitization in Cerebrovascular Disease, Interventional Neuroradiology, 10.15274/INR-2014-10002, 20:1, (5-11), Online publication date: 1-Jan-2014. De Luca G, Verdoia M, Binda G, Schaffer A, Suryapranata H and Marino P (2013) Aspirin desensitization in patients undergoing planned or urgent coronary stent implantation. A single-center experience, International Journal of Cardiology, 10.1016/j.ijcard.2012.01.063, 167:2, (561-563), Online publication date: 1-Jul-2013. Barillà F, Pulcinelli F, Mangieri E, Torromeo C, Tanzilli G, Dominici T, Pellicano M, Paravati V, Acconcia M and Gaudio C (2012) Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention, Platelets, 10.3109/09537104.2012.686072, 24:3, (183-188), Online publication date: 1-May-2013. Latib A, Ielasi A, Ferri L, Chieffo A, Godino C, Carlino M, Montorfano M and Colombo A (2013) Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: A proposed alternative regimen, International Journal of Cardiology, 10.1016/j.ijcard.2011.08.080, 165:3, (444-447), Online publication date: 1-May-2013. Pattanaik D, Lieberman P and Das P (2012) Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist, Future Cardiology, 10.2217/fca.12.38, 8:4, (555-562), Online publication date: 1-Jul-2012. Lambrakis P, Rushworth G, Adamson J and Leslie S (2011) Aspirin hypersensitivity and desensitization protocols: implications for cardiac patients, Therapeutic Advances in Drug Safety, 10.1177/2042098611422558, 2:6, (263-270), Online publication date: 1-Dec-2011. Ozyigit L, Galera C, Bousquet P, Piot C and Demoly P (2011) Protocole d'induction de tolérance pour l'hypersensibilité à l'aspirine, Revue Française d'Allergologie, 10.1016/j.reval.2010.11.002, 51:5, (485-491), Online publication date: 1-Sep-2011. Fajt M and Petrov A (2011) Outpatient Aspirin Desensitization for Patients With Aspirin Hypersensitivity and Cardiac Disease, Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine, 10.1097/HPC.0b013e318213d5a6, 10:1, (17-21), Online publication date: 1-Mar-2011. Collins S, Syed A and Waksman R (2010) Pharmacology in the Cardiac Catheterization Laboratory Cardiovascular Interventions in Clinical Practice, 10.1002/9781444316704.ch41, (428-447), Online publication date: 10-May-2010. Tran T and Muelleman R (2010) Allergy, Hypersensitivity, and Anaphylaxis Rosen's Emergency Medicine – Concepts and Clinical Practice, 10.1016/B978-0-323-05472-0.00117-1, (1511-1528), . Rossini R, Angiolillo D, Musumeci G, Scuri P, Invernizzi P, Bass T, Mihalcsik L and Gavazzi A (2008) Aspirin Desensitization in Patients Undergoing Percutaneous Coronary Interventions With Stent Implantation, The American Journal of Cardiology, 10.1016/j.amjcard.2007.10.045, 101:6, (786-789), Online publication date: 1-Mar-2008. Shaker M, Lobb A, Jenkins P, O'Rourke D, Takemoto S, Sheth S, Burroughs T and Dykewicz M (2008) An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease, Journal of Allergy and Clinical Immunology, 10.1016/j.jaci.2007.06.047, 121:1, (81-87), Online publication date: 1-Jan-2008. (2007) Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST, Revista Española de Cardiología, 10.1157/13111518, 60:10, (1070.e1-1070.e80), Online publication date: 1-Oct-2007. Jenneck C, Juergens U, Buecheler M and Novak N (2007) Pathogenesis, diagnosis, and treatment of aspirin intolerance, Annals of Allergy, Asthma & Immunology, 10.1016/S1081-1206(10)60615-1, 99:1, (13-21), Online publication date: 1-Jul-2007. Arampatzis C and Kanonidis G (2007) Immunoallergic syndromes in interventional cardiology Common Clinical Dilemmas in Percutaneous Coronary Interventions, 10.3109/9780203089811-2, (1-7), Online publication date: 13-Feb-2007. Kong J, Teuber S and Gershwin M (2007) Aspririn and nonsteroidal anti-inflammatory drug hypersensitivity, Clinical Reviews in Allergy & Immunology, 10.1007/BF02686086, 32:1, (97-109), Online publication date: 1-Feb-2007. Page N and Schroeder W (2016) Rapid Desensitization Protocols for Patients with Cardiovascular Disease and Aspirin Hypersensitivity in an Era of Dual Antiplatelet Therapy, Annals of Pharmacotherapy, 10.1345/aph.1H437, 41:1, (61-67), Online publication date: 1-Jan-2007. Ebo D, Hagendorens M, Bridts C and Stevens W (2014) IMMEDIATE-TYPE ALLERGY TO DRUGS AND RELATED COMPOUNDS: EVALUATION AND MANAGEMENT, Acta Clinica Belgica, 10.1179/acb.2005.053, 60:6, (350-361), Online publication date: 1-Dec-2005. Patrono C, García Rodríguez L, Landolfi R and Baigent C (2005) Low-Dose Aspirin for the Prevention of Atherothrombosis, New England Journal of Medicine, 10.1056/NEJMra052717, 353:22, (2373-2383), Online publication date: 1-Dec-2005. Fox D, Gray T and Fath-Ordoubadi F (2017) Myocardial Infarction after Aspirin Treatment, Journal of the Royal Society of Medicine, 10.1177/014107680509800108, 98:1, (21-23), Online publication date: 1-Jan-2005. July 6, 2004Vol 110, Issue 1 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000134306.28561.2APMID: 15238467 Originally publishedJuly 6, 2004 PDF download Advertisement SubjectsPharmacologyPlatelets
Referência(s)